Abstract
Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Keywords: Disease-modifying drugs, PPAR, stroke.
Current Drug Targets
Title:PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke
Volume: 14 Issue: 7
Author(s): Thavarak Ouk, Camille Potey, Sophie Gautier, Michele Bastide, Dominique Deplanque, Bart Staels, Patrick Duriez, Didier Leys and Regis Bordet
Affiliation:
Keywords: Disease-modifying drugs, PPAR, stroke.
Abstract: Stroke is one of the major causes of mortality and disability in adults in industrialized countries. Despite numerous preclinical studies and clinical trials in the field of cerebral ischemia, no pharmacological agent has been validated in the treatment of acute ischemic, except thrombolysis. Cerebral ischemia is not only a neuronal disease but it affects the entire neurovascular unit. The therapeutic strategy in stroke should be more global and combine preventive approaches, acute phase treatment and long-term care to improve recovery and prevent or treat affective and cognitive post-stroke consequences. There is an imperative need to develop disease-modifying drugs, which should be able to induce neuroprotection, to serve as adjuvants for thrombolysis by decreasing the hemorrhagic risk and to limit the long-term post-stroke consequences. This review presents the potential effects of Peroxisome Proliferator-Activated Receptors (PPARs) and of their agonists in stroke. We focus on each PPAR receptor and detail their implication in stroke. PPARs are nuclear receptors, acting as ligand-dependent transcription factors. They are expressed in the neurovascular unit that suggests that PPARs could play a role in stroke. Indeed, it has been shown that they are able to interfere with pathways implicated in the pathophysiology of stroke. They could be an answer to this disease-modifying drug concept, being able to act on the different phases of ischemia.
Export Options
About this article
Cite this article as:
Ouk Thavarak, Potey Camille, Gautier Sophie, Bastide Michele, Deplanque Dominique, Staels Bart, Duriez Patrick, Leys Didier and Bordet Regis, PPARs: A Potential Target for a Disease-Modifying Strategy in Stroke, Current Drug Targets 2013; 14 (7) . https://dx.doi.org/10.2174/1389450111314070005
DOI https://dx.doi.org/10.2174/1389450111314070005 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Stroke as a Consequence of Sleep Apnea: Epidemiology, Pathophysiology and Treatment Strategies
Current Respiratory Medicine Reviews Drug-Eluting Stents: Present and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Artificial Neural Network Models for Coronary Artery Disease
Current Bioinformatics Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview
Cardiovascular & Hematological Disorders-Drug Targets Simultaneous Determination of Fenofibrate, its Metabolite and Co- Formulated/Administered Statins Using Reverse Phase TLC-Densitometry and HPLC-UV Methods: Application in Human Plasma
Current Chromatography Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives
Current Drug Targets Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Increased Severity of Acute Cerebral Ischemic Injury Correlates with Enhanced Stem Cell Induction as well as with Predictive Behavioral Profiling
Current Neurovascular Research Fluorescent Probes for Cellular Assays
Combinatorial Chemistry & High Throughput Screening The Relevance of New Drug Combinations for Modern Tuberculosis Treatment - A Patent Perspective
Recent Patents on Anti-Infective Drug Discovery Current Status of Carotid Stenting
Current Vascular Pharmacology Macrophages: Promising Targets for the Treatment of Atherosclerosis
Current Vascular Pharmacology A Perspective on the Current Strategies for the Treatment of Obesity
Current Drug Targets - CNS & Neurological Disorders A Review of the Current Role of Blood Clotting Analyzers in Clinical Practice
Cardiovascular & Hematological Disorders-Drug Targets Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Cyclooxygenase-2 Inhibitors and Cancer (Guest Editor: J.-P. Henichart)]
Anti-Cancer Agents in Medicinal Chemistry Valproic Acid Attenuates Neuronal Loss in the Brain of APP/PS1 Double Transgenic Alzheimer’s Disease Mice Model
Current Alzheimer Research Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology High-accuracy Automated Diagnosis of Parkinson's Disease
Current Medical Imaging Characterizing the Binding of Angiotensin Converting Enzyme I Inhibitory Peptide to Human Hemoglobin: Influence of Electromagnetic Fields
Protein & Peptide Letters